These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 10880026

  • 1. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
    Todo T, Rabkin SD, Martuza RL.
    Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
    [Abstract] [Full Text] [Related]

  • 2. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.
    Cancer Res; 2001 Dec 15; 61(24):8743-50. PubMed ID: 11751394
    [Abstract] [Full Text] [Related]

  • 3. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
    Wildner O, Morris JC.
    Cancer Res; 2000 Aug 01; 60(15):4167-74. PubMed ID: 10945625
    [Abstract] [Full Text] [Related]

  • 4. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells.
    Balzarini J, Degrève B, Andrei G, Neyts J, Sandvold M, Myhren F, de Clercq E.
    Gene Ther; 1998 Mar 01; 5(3):419-26. PubMed ID: 9614564
    [Abstract] [Full Text] [Related]

  • 5. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL.
    Cancer Gene Ther; 2000 Feb 01; 7(2):275-83. PubMed ID: 10770637
    [Abstract] [Full Text] [Related]

  • 6. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG.
    Cancer Res; 2001 Apr 01; 61(7):2983-95. PubMed ID: 11306477
    [Abstract] [Full Text] [Related]

  • 7. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
    Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL.
    Mol Ther; 2000 Dec 01; 2(6):588-95. PubMed ID: 11124059
    [Abstract] [Full Text] [Related]

  • 8. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
    Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, Nicholas T, Kruse CA.
    Cancer Gene Ther; 2002 Jan 01; 9(1):87-95. PubMed ID: 11916247
    [Abstract] [Full Text] [Related]

  • 9. Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy.
    Miura F, Moriuchi S, Maeda M, Sano A, Maruno M, Tsanaclis AM, Marino R, Glorioso JC, Yoshimine T.
    Gene Ther; 2002 Dec 01; 9(24):1653-8. PubMed ID: 12457278
    [Abstract] [Full Text] [Related]

  • 10. [Bystander effect mediated by herpes simplex virus-thymidine kinase/ganciclovir approach on prostatic cancer cells and its regulation].
    Xing Y, Lu G, Xiao Y, Zeng F, Zhang Q, Xiong P, Feng W.
    Zhonghua Yi Xue Za Zhi; 2002 Nov 10; 82(21):1484-7. PubMed ID: 12509912
    [Abstract] [Full Text] [Related]

  • 11. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 12. Connexin 43-enhanced suicide gene therapy using herpesviral vectors.
    Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, Goins WF, Cohen JB, Glorioso JC.
    Mol Ther; 2000 Jan 01; 1(1):71-81. PubMed ID: 10933914
    [Abstract] [Full Text] [Related]

  • 13. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses.
    Wildner O, Morris JC.
    J Gene Med; 2000 Jan 01; 2(5):353-60. PubMed ID: 11045429
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
    Nakano K, Todo T, Chijiiwa K, Tanaka M.
    Mol Ther; 2001 Apr 01; 3(4):431-7. PubMed ID: 11319903
    [Abstract] [Full Text] [Related]

  • 15. (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells.
    Hamel W, Zirkel D, Mehdorn HM, Westphal M, Israel MA.
    Cancer Gene Ther; 2001 May 01; 8(5):388-96. PubMed ID: 11477459
    [Abstract] [Full Text] [Related]

  • 16. Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals.
    Su H, Lu R, Ding R, Kan YW.
    Mol Ther; 2000 Jun 01; 1(6):509-15. PubMed ID: 10933975
    [Abstract] [Full Text] [Related]

  • 17. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.
    Moriuchi S, Krisky DM, Marconi PC, Tamura M, Shimizu K, Yoshimine T, Cohen JB, Glorioso JC.
    Gene Ther; 2000 Sep 01; 7(17):1483-90. PubMed ID: 11001368
    [Abstract] [Full Text] [Related]

  • 18. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.
    Tyynelä K, Sandmair AM, Turunen M, Vanninen R, Vainio P, Kauppinen R, Johansson R, Vapalahti M, Ylä-Herttuala S.
    Cancer Gene Ther; 2002 Nov 01; 9(11):917-24. PubMed ID: 12386830
    [Abstract] [Full Text] [Related]

  • 19. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
    Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S, Chang M, Lanuti M, Black ME, Kaiser LR, Albelda SM.
    Cancer Gene Ther; 2003 May 01; 10(5):353-64. PubMed ID: 12719705
    [Abstract] [Full Text] [Related]

  • 20. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
    Todo T, Rabkin SD, Chahlavi A, Martuza RL.
    Hum Gene Ther; 1999 Nov 20; 10(17):2869-78. PubMed ID: 10584932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.